Thyronorm Oral Solution For Cats 30Ml

Target species Cats Indications for use, specifying the target species For the stabilisation of hyperthyroidism in cats prior to surgical thyroidectomy. For the long term treatment of feline hyperthyroidism. Contraindications Do not use in cats suffering from systemic disease such as primary liver disease or diabetes mellitus. Do not use in cats showing signs of autoimmune disease. Do not use in animals with disorders of white blood cells, such as neutropenia and lymphopenia. Do not use in animals with platelet disorders and coagulopathies (particularly thrombocytopenia). Do not use in pregnant or lactating females. Please refer to section, "Use during pregnancy, lactation or lay" Do not use in case of hypersensitivity to the active substance or to any of the excipients. Special warnings for each target species In order to enhance stabilisation of the hyperthyroid patient the same feeding and dosing schedule should be used daily. Special precautions for use Special precautions for use in animals If more than 10 mg per day is required animals should be monitored particularly carefully. Use of the product in cats with renal dysfunction should be subject to careful risk:benefit assessment by the clinician. Due to the effect thiamazole can have on reducing the glomerular filtration rate, the effect of therapy on renal function should be monitored closely as deterioration of an underlying condition may occur. Haematology must be monitored due to risk of leucopenia or haemolytic anaemia. Any animal that suddenly appears unwell during therapy, particularly if they are febrile, should have a blood sample taken for routine haematology and biochemistry. Neutropenic animals (neutrophil counts <2.5 x 109/l) should be treated with prophylactic bactericidal antibacterial drugs and supportive therapy. Please refer to section, "Amounts to be administered and administration route" for monitoring instructions. As thiamazole can cause haemoconcentration, cats should always have access to drinking water. Special precautions to be taken by the person administering the veterinary medicinal product to animals People with known hypersensitivity (allergy) to thiamazole or one of the excipients should avoid contact with the veterinary medicinal product. If allergic symptoms develop, such as a skin rash, swelling of the face, lips or eyes or difficulty in breathing, you should seek medical attention immediately and show the package leaflet or label to the doctor. Thiamazole may cause gastrointestinal disturbances, headache, fever, joint pain, pruritus (itching) and pancytopaenia (decrease in blood cells and platelets). Avoid dermal and oral exposure, including hand-to-mouth contact. Do not eat, drink or smoke while handling the product or used litter. Wash hands with soap and water after administration of the product and handling the vomit of or litter used by treated animals. Wash any spillages from skin immediately. Following administration of the product any residual product remaining on the tip of the dosing syringe should be wiped clean with a tissue. The contaminated tissue should be immediately disposed of. The used syringe should be stored with the product in the original carton. This product may cause eye irritation. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician. Avoid eye contact including hand to eye contact. In case of accidental eye contact, rinse eyes immediately with clean running water. If irritation develops, seek medical advice. As thiamazole is a suspected human teratogen, women of child-bearing age must wear non-permeable single use gloves when administering the product or handling the litter/vomit of treated cats. If you are pregnant, think you may be pregnant or are attempting to conceive, you should not administer the product or handle the litter/vomit of treated cats. Adverse reactions (frequency and seriousness) Adverse reactions have been reported following long term control of hyperthyroidism. In many cases, signs may be mild and transitory and not a reason for withdrawal of treatment. The more serious effects are mainly reversible when medication is stopped. Adverse reactions are uncommon. The most common clinical side effects that are reported include vomiting, inappetence/anorexia, lethargy, severe pruritus and excoriations of the head and neck, bleeding diathesis and icterus associated with hepatopathy, and haematological abnormalities (eosinophilia, lymphocytosis, neutropenia, lymphopenia, slight leucopenia, agranulocytosis, thrombocytopenia or haemolytic anaemia). These side effects resolve within 7 – 45 days after cessation of thiamazole therapy. Possible immunological side effects include anaemia, with rare side effects including thrombocytopenia and serum anti-nuclear antibodies, and, very rarely, lymphadenopathy can occur. Treatment should be stopped immediately and alternative therapy considered following a suitable period of recovery. Following long-term treatment with thiamazole in rodents, an increased risk of neoplasia in the thyroid gland has been shown to occur, but no evidence is available in cats. Use during pregnancy, lactation or lay Laboratory studies in rats and mice have shown evidence of teratogenic and embryotoxic effects of thiamazole. In cats, the safety of the veterinary medicinal product has not been established during pregnancy or lactation. Do not use in pregnant or lactating females. From man and rats it is known that the drug can cross the placenta and concentrates in the foetal thyroid gland. There is also a high rate of transfer into breast milk. Interaction with other medicinal products and other forms of interaction Concurrent treatment with phenobarbital may reduce the clinical efficacy of thiamazole. Thiamazole is known to reduce the hepatic oxidation of benzimidazole wormers and may lead to increases in their plasma concentrations when given concurrently. Thiamazole is immunomodulatory, therefore this should be taken into account when considering vaccination programmes.